Dr. Reddy’s details June 2026 investor meetings

Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule of analyst and institutional investor meetings.

Accepted by SEC EDGAR 06/10/2026 - 11:28 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule of analyst and institutional investor meetings. The company’s management plans to participate in an Investec investor conference in London from June 16, 2026 to June 17, 2026, with in-person group meetings scheduled between 09:00 and 17:00 BST. The company notes that this schedule may change depending on circumstances for either the investors or the company.

Key Figures

Investor meeting dates: June 16–17, 2026 Meeting hours: 09:00–17:00 BST

2 metrics

Investor meeting dates June 16–17, 2026 Investec investor conference in London

Meeting hours 09:00–17:00 BST Daily schedule for group meetings

Key Terms

Regulation 30, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, analyst / institutional investor meetings, foreign private issuer

4 terms

Regulation 30 regulatory

"Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory

"under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

analyst / institutional investor meetings financial

"Schedule of Analyst / Institutional Investor Meetings"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dr. Reddy’s Laboratories (RDY) disclose in this Form 6-K?

Dr. Reddy’s Laboratories disclosed its schedule of analyst and institutional investor meetings. Management will attend an Investec investor conference in London, holding in-person group meetings over two days. The notice is made under Regulation 30 of SEBI’s disclosure rules.

When will Dr. Reddy’s (RDY) meet analysts and institutional investors?

Dr. Reddy’s management plans meetings from June 16, 2026 to June 17, 2026. These meetings will occur during an Investec investor conference, with sessions scheduled throughout each day between 09:00 and 17:00 British Summer Time.

Where will Dr. Reddy’s (RDY) investor meetings take place in June 2026?

The investor meetings will take place in London at an Investec-organized conference. The meetings are described as in-person group meets, giving institutional investors direct access to the company’s management over two consecutive days.

What is the nature and mode of Dr. Reddy’s June 2026 investor meetings?

The meetings are described as in-person group meetings with single institution or investor groups. Management will engage multiple investors in a conference setting, rather than one-on-one calls or virtual-only formats, according to the disclosed schedule details.

Can the June 2026 Dr. Reddy’s (RDY) investor meeting schedule change?

Yes, the company states the schedule is subject to change. Any exigencies on the part of investors or the company may require adjustments, so the disclosed timetable is indicative rather than guaranteed.

Under which regulation was Dr. Reddy’s (RDY) investor meeting schedule disclosed?

The company disclosed the investor meeting schedule under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation governs timely disclosure of material events and information by listed entities in India.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

June, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                           Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                            No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated June 10, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: June 10, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

June 10, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings

This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups:

Date	Organized by	Location	Meeting mode	Nature of meet	Timing
16.06.2026 -17.06.2026	Investec	London	In-Person	Group Meet	09:00 - 17:00 BST

Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.

This is for your information.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 33.5 KB